Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Journal of Medical Economics|December 2, 2024
The impact of KRAS mutational status on patient-reported outcomes in advanced non-small-cell lung cancer: a cross sectional study in France and GermanyChristos Chouaid, Andromachi Giannopoulou, Alexandra Starry, et al.
Lung Cancer (Amsterdam, Netherlands)|September 1, 2023
Immune checkpoint inhibitors in non-small cell lung cancer - When should we dare to stop treatment?Farastuk Bozorgmehr, Annette Müller, Justyna Rawluk, et al.
Clinical and Translational Science|November 22, 2020
Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer using the CYP3A Inhibitor CobicistatNicolas Hohmann, Farastuk Bozorgmehr, Petros Christopoulos, et al.
Clinical Imaging|December 3, 2014
Invasive lung cancer staging: influence of CT-guided core needle biopsy on onset of pleural carcinomatosisPaul Flechsig, Josef Kunz, Claus-Peter Heussel, et al.
ESMO Open|December 6, 2019
Awareness of predatory journals and open access among medical oncologists: results of an online surveyGeorg Richtig, Erika Richtig, Alexandra Böhm, et al.
BMC Cancer|August 27, 2020
Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trialFarastuk Bozorgmehr, Inn Chung, Petros Christopoulos, et al.
Stem Cells (Dayton, Ohio)|July 7, 2007
No evidence of clonal dominance in primates up to 4 years following transplantation of multidrug resistance 1 retrovirally transduced long-term repopulating cellsFarastuk Bozorgmehr, Stefanie Laufs, Stephanie E Sellers, et al.
Frontiers in Oncology|May 7, 2021
Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung CancerMei Elsayed, Farastuk Bozorgmehr, Daniel Kazdal, et al.
BMC Cancer|June 29, 2021
Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trialPetros Christopoulos, Farastuk Bozorgmehr, Lena Brückner, et al.
Trials|April 24, 2020
Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trialJonas Kuon, Adriane Hommertgen, Johannes Krisam, et al.
Pageof 6